Inspirata Announces New Software Release and Partnership with Hamamatsu at Digital Pathology & AI Congress in London, December 6-7
Visit stand 30 at the 5th Digital Pathology and AI Congress, London to learn how Inspirata is igniting digital pathology with new software features and functions in release v2.0.8.
London, United Kingdom, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata® Europe, Ltd. today revealed it has entered into a partnership agreement with Hamamatsu Photonics affording shared customers with the ability to view native Hamamatsu .ndpi images within Inspirata’s Dynamyx™ digital pathology software. Inspirata and Hamamatsu will also be showcasing the many benefits this technical partnership will bring to clinical laboratories as part of both providers’ scheduled participation in Digital Pathology & AI Congress, London.
“By bringing on new leading scanner partners and enhancing the viewer capabilities, Dynamyx™ is positioning itself as the nucleus of a digital pathology ecosystem,” says Inspirata Founder Dr. Mark Lloyd. “We are thrilled to be seamlessly integrated with the high quality Whole Slide Images produced by the diverse line of Hamamatsu scanners, as it gives our joint clients an exemplary user experience while protecting any previous investment in scanners and allowing for the growth of new instruments.”
The Hamamatsu integration is included as part of release v2.0.8, comes just three months after Inspirata’s last major update and further exemplifies the partnership philosophy which underpins their mission and vision. “We are bringing scanners, image analysis algorithms and AP-LIS/ LIMS vendors together to create a comprehensive digital workflow which empowers pathologists to work more efficiently and effectively,” says General Manager of Inspirata Europe, Ltd. Tim Wing. “With the Royal College of Pathologists’ 2018 Histopathology Workforce Surveyi surfacing just three percent of histopathology departments in the UK possess sufficient staff to meet demand, equipping those covering the shortfall to work smarter is imperative. The pathology and laboratory community are desperately appealing for providers to work closer together for the betterment of patients and this partnership speaks to what can be achieved when they do.”
“Hamamatsu Photonics is delighted to collaborate with Inspirata and is excited that our renowned range of WSI scanners will form a key part of such an integrated digital pathology workflow solution,” explains Hamamatsu Photonics Europe Nanozoomer Product Manager Emmanuel Pirson. “We expect this partnership to contribute to an accelerated uptake of integrated digital pathology solutions within the European clinical market. Likewise, this collaboration represents just one of a number of steps our Company is taking to increase awareness and acceptance of digital pathology.”
With orders placed for a single Nanozoomer S60 and two Nanozoomer S360, one of the early beneficiaries of the Inspirata and Hamamatsu partnership will be Path Links in Lincoln. Representing one of the largest clinical pathology networks in the UK, Path Links serves a population of approximately one million and processes four and a half million specimens each year. “When undertaking a transformation as significant as migrating from analogue to digital pathology, it is essential to have the freedom as an institution to select the blend of providers which most appropriately match your requirements,” says Mick Chomyn, Path Links General Manager. “Having spent the last few months really putting them through their paces, we are confident that the Hamamatsu scanners represent an excellent fit and will serve to complement our existing scanner investments.”
Located at stand 30 at Digital Pathology & AI Congress, event attendees will be able to participate in interactive demonstrations of the Dynamyx digital pathology workflow software and explore for themselves how real-time collaboration, case-sharing, workflow algorithms and AI-based image analysis APIs functionality could be utilized to assist their laboratory reduce turnaround times. In addition, Inspirata and Hamamatsu will be participating in a joint Congress workshop in which they will spotlight their new integration on December 7th 1.45-2.30. Registration for this workshopii is now open and can be accessed via the link here.
The pressures on pathology departments are increasing. Inspirata’s advanced workflow-centric tools and ‘open’ architecture are critical enablers of digital adoption as a way to alleviate these challenges.
About Hamamatsu Photonics
Hamamatsu has a decade of real world experience in delivering sophisticated whole slide imaging (WSI) solutions across the globe. Hamamatsu’s NanoZoomer whole slide scanner series quickly transform entire histology and cytology glass slides into diagnostic-quality digital images for duplication, annotation, storage, retrieval, and image sharing. Our intuitive viewer software and patented navigation map technique enable users to scan slides in a variety of modes and share images across networks. Applications include routine and computer-aided diagnosis in laboratories, research, education, and telepathology.
About Inspirata Europe Ltd.
Inspirata® Europe Ltd. provides oncology diagnostics workflow solutions that span digital pathology; diagnostic and predictive assays; and precision medicine. It also offers cancer informatics workflows that, in combination with its Natural Language Processing (NLP) and Artificial Intelligence (AI) algorithms structures unstructured case files and clinician notes to provide key insights for oncology-specific clinical and operational activities as well as cancer reporting. Inspirata’s flagship solution is its Cancer Information Data Trust (CIDT) that generates a longitudinal view of oncology patients—from diagnosis, through treatments and therapies, to outcomes. The CIDT has extensive applications in clinical decision support, research, education, drug discovery and clinical trials enrollment. Its use will extend to physicians, patients, researchers, pharma and others. For more information, please visit www.inspirata.com or contact email@example.com.
i Royal College of Pathologists Histopathology Workforce Survey – link here
ii The workshop is only open to those registered to attend Digital Pathology & AI Congress.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
SDRL – Seadrill Limited Announces Contract Award for the West Gemini17.7.2019 22:35:00 CEST | Press release
Hamilton, Bermuda, July 17, 2019 - Seadrill Limited ("Seadrill" or "the Company") has secured a nine well contract with three options, each for two wells, for the West Gemini in West Africa. Total contract value for the firm portion of the contract is expected to be approximately $84 million with commencement expected in early Q4 2019 and running through Q4 2020. FORWARD LOOKING STATEMENTS This news release includes forward looking statements. Such statements are generally not historical in nature, and specifically include statements about the Company's plans, strategies, business prospects, changes and trends in its business, the markets in which it operates and its restructuring efforts. These statements are made based upon management's current plans, expectations, assumptions and beliefs concerning future events impacting the Company and therefore involve a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or imp
GrandVision confirms HAL and EssilorLuxotica are engaged in discussions on a possible sale of controlling interest of HAL in GrandVision17.7.2019 18:45:00 CEST | Press release
Schiphol, The Netherlands - 17 July 2019. GrandVision NV (Euronext: GVNV) confirms that it has been approached by EssilorLuxottica SA (Euronext: EL) and HAL Holding NV (Euronext: HAL) in connection with a possible sale of HAL’s 76.72% ownership interest in GrandVision to EssilorLuxottica at an envisaged purchase price per share of approximately EUR28.00. At this stage it is uncertain whether an agreement between EssilorLuxottica and HAL will be reached. While a transaction would be between HAL and EssilorLuxottica, GrandVision’s support has been requested. Completion of a sale of HAL’s ownership interest in GrandVision would be subject to customary conditions including approval from relevant regulatory authorities in various jurisdictions, which may take between 12 and 24 months. Following completion of the transaction between HAL and EssilorLuxottica, EssilorLuxottica will make a (mandatory) public offer for all shares in GrandVision. Further announcements will be made if and when req
Solutions 30 : 79.8% revenue growth in the first half of 201917.7.2019 18:00:00 CEST | Press release
79.8% revenue growth in the first half of 2019 France: revenue up 74.4% Other countries: revenue up 90.3% Reliable, cash-generating model Solutions 30 SE, the European leader in solutions for new technologies, today disclosed its revenue for the first half of 2019 . In millions of euros (Unaudited figures) HY Q2 2019 2018 % change 2019 2018 % change Total 317.8 176.7 +79.8% 157.4 91.5 +72.1% From France 202.8 116.3 +74.4% 101.5 59.5 +70.6% From other countries 115.0 60.4 +90.3% 55.9 32.0 +74.7% Sustained growth trend continues Solutions 30 maintains its high growth trajectory, disclosing revenues of €317.8 million for the first half of 2019, a 79.8% increase (36.9% of which was organic growth1). For the 2nd quarter alone, revenue increased by 72.1%, reaching €157.4 million. Organic growth represented 32.3%. The group continues to demonstrate the relevance of its positioning and strategy in markets driven by the economy’s digital transformation and major technology groups’ outsourcing o
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban17.7.2019 18:00:00 CEST | Press release
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA - July 17, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today hosted a key opinion leader (KOL) meeting in New York City on in-vitro fertilization (IVF). At the event, three KOLs in women’s reproductive health along with company executives discussed trends in IVF, including current practice trends toward Day 5 embryo transfer, and the merits of single-embryo transfer (SET) vs. double embryo transfer (DET). Further, event participants discussed the potential clinical importance of nolasiban, ObsEva’s oral oxytocin receptor antagonist, to significantly improve the live birth rate (LBR) resulting from ET, and address the high physical, emotional and financial pain associated with fa
Bizagi goes from Stealth to Hyper Growth Delivering Digital Transformation for World Leading Brands17.7.2019 18:00:00 CEST | Press release
From Adidas and Audi to Ikea and the U.S. government, Bizagi’s unique Intelligent Process Automation helping organizations harness the power of RPA and AI to speed transformation SANTA CLARA, Calif., July 17, 2019 (GLOBE NEWSWIRE) -- Bizagi, the world’s leading Intelligent Process Automation platform provider, today announced significant growth in the U.S. and abroad driven by its success enabling digital transformation for world leading brands such as DHL, Gap, Citizens Bank, AON and numerous U.S. government agencies including the Departments of Agriculture, Defense, Energy, HHS, Homeland Security and many others. Bizagi’s growth is based on enterprise adoption of its unique Intelligent Process Automation, enabling companies to better leverage digital and robotic processes, along with artificial intelligence, to improve customer interaction, speed operations and build revenue. This news follows the company’s recognition last month as a leader in The Forrester Wave™: Software for Digit
EnBW International Finance B.V.: Half-yearly report17.7.2019 17:00:00 CEST | Press release
EnBW International Finance B.V.: Half-yearly report 2019 In accordance with the Transparency Directive (Directive 2004/109/EC), as amended by the Transparency Directive Amending Directive (Directive 2013/50/EU), and following the choice of EnBW International Finance B.V. for The Netherlands as Home Member State, EnBW International Finance B.V. hereby informs that the half-year financial reports for the period 1 January 2019 till 30 June 2019 have been filed on 17 July 2019 with the Autoriteit Financiële Markten (AFM) in The Netherlands and are available on the internet site: https://www.enbw.com/unternehmen/investoren/news-und-publikationen/publikationen/